Aurinia Pharmaceuticals Inc.

Equities

AUPH

CA05156V1022

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:01 2024-05-16 pm EDT			5-day change	1st Jan Change
5.755 ^USD	+8.38%		+11.32%	-35.98%

May. 14	Aurinia Pharmaceuticals Inc. Presented Results from the Analysis Showing Lupkynis A Cost-Effective Treatment for Lupus Nephritis Presented At National Kidney Foundation's Spring Clinical Meeting 2024	CI
May. 07	Lucien Selce Urges Aurinia Pharmaceuticals Board to Take Action to Enhance Shareholder Value	CI

Institutional Shareholder Services Inc Recommends Aurinia Shareholders Vote Against the Company’s Named Executive Officers’ Compensation

May 03, 2023 at 02:20 pm EDT

On May 3, 2023, MKT Capital Ltd. announced that Institutional Shareholder Services Inc. (ISS), has recommended shareholders vote against the ratification of Aurinia Pharmaceuticals's named executive officers' (NEOs) compensation at the upcoming 2023 Annual General Meeting of Shareholders scheduled to be held on May 17, 2023.

Latest news about Aurinia Pharmaceuticals Inc.

Aurinia Pharmaceuticals Inc. Presented Results from the Analysis Showing Lupkynis A Cost-Effective Treatment for Lupus Nephritis Presented At National Kidney Foundation's Spring Clinical Meeting 2024	May. 14	CI
Lucien Selce Urges Aurinia Pharmaceuticals Board to Take Action to Enhance Shareholder Value	May. 07	CI
Transcript : Aurinia Pharmaceuticals Inc., Q1 2024 Earnings Call, May 02, 2024	May. 02
Earnings Flash (AUPH) AURINIA PHARMACEUTICALS Posts Q1 Revenue $50.3M, vs. Street Est of $47.1M	May. 02	MT
Aurinia Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02	CI
Aurinia Pharmaceuticals Inc. Reiterates Revenue Guidance for the Fiscal Year 2024	May. 02	CI
Aurinia Pharmaceuticals Inc. Announces The U.S. Food & Drug Administration Approves Updated LUPKYNIS® Label to include Long-Term Data from the AURORA Clinical Program	Apr. 30	CI
ILJIN SNT Delivers a Letter to Aurinia Pharmaceuticals	Mar. 20	CI
Aurinia Pharmaceuticals Insider Sold Shares Worth $711,094, According to a Recent SEC Filing	Mar. 07	MT
Aurinia Pharmaceuticals Insider Sold Shares Worth $323,372, According to a Recent SEC Filing	Mar. 07	MT
HC Wainwright Cuts Price Target on Aurinia Pharmaceuticals to $13 From $15, Maintains Buy Rating	Feb. 22	MT
RBC Cuts Price Target on Aurinia Pharmaceuticals to $8 From $13, Keeps Outperform, Speculative Risk	Feb. 16	MT
Sector Update: Health Care Stocks Higher Late Afternoon	Feb. 15	MT
Sector Update: Health Care Stocks Higher Thursday Afternoon	Feb. 15	MT
Sector Update: Health Care	Feb. 15	MT
Aurinia Pharmaceuticals Q4 Loss Widens, Revenue Increases; Concludes Strategic Review -- Shares Slump	Feb. 15	MT
Transcript : Aurinia Pharmaceuticals Inc., Q4 2023 Earnings Call, Feb 15, 2024	Feb. 15
Aurinia Pharmaceuticals Inc. announces an Equity Buyback for $150 million worth of its shares.	Feb. 15	CI
Earnings Flash (AUPH) AURINIA PHARMACEUTICALS Posts Q4 Revenue $45.1M, vs. Street Est of $45.2M	Feb. 15	MT
Aurinia Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 15	CI
Aurinia Pharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 15	CI
Aurinia Pharmaceuticals Inc. Provides Revenue Guidance for the Fiscal Year 2024	Feb. 15	CI
AURINIA PHARMACEUTICALS FINDS NO BUYER, TO ANNOUNCE $1…	Feb. 15	RE
Kidney drug developer Aurinia fails to clinch a sale, sources say	Feb. 15	RE
Aurinia Pharmaceuticals Inc. authorizes a Buyback Plan.	Feb. 14	CI

Chart Aurinia Pharmaceuticals Inc.

Duration

Period

More charts

Company Profile

Aurinia Pharmaceuticals Inc. is a Canada-based fully integrated biopharmaceutical company. The Company is focused on delivering therapies to treat targeted patient populations with a high unmet medical need that are impacted by autoimmune, kidney and rare diseases. The Company has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct pre-clinical, clinical, and regulatory activities to support the voclosporin development program. LUPKYNIS is a calcineurin inhibitor (CNI) immunosuppressant, that improves near and long-term outcomes in LN when used in combination with mycophenolate mofetil (MMF) and steroids. LUPKYNIS reduces cytokine activation and blocks interleukin IL-2 expression and T-cell mediated immune responses. Voclosporin, the active ingredient in LUPKYNIS, is made by a modification of a single amino acid of the cyclosporine molecule. Its product pipeline includes AUR200 and AUR300.

Sector

Biotechnology & Medical Research

Calendar

2024-06-14 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Aurinia Pharmaceuticals Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

5.77 USD

Average target price

10.14 USD

Spread / Average Target

+75.79%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
AURINIA PHARMACEUTICALS INC.	-35.98%	823M
VERTEX PHARMACEUTICALS INCORPORATED	+8.29%	114B
REGENERON PHARMACEUTICALS, INC.	+10.21%	104B
ARGENX SE	+0.79%	22.28B
BIONTECH SE	-11.90%	22.41B
GENMAB A/S	-5.38%	19.07B
WUXI APPTEC CO., LTD.	-37.36%	18B
BEIGENE, LTD.	-5.17%	17.89B
NEUROCRINE BIOSCIENCES, INC.	+7.70%	14.28B
SAREPTA THERAPEUTICS, INC.	+37.65%	12.55B

Bio Therapeutic Drugs